Table 1.
Baseline characteristic of included patients.
| Spain n=84 |
Mexico n=222 |
Korea n=274 |
USA n=291 |
Colombia n=40 |
France n=66 |
Brazil n=90 |
India n=366 |
Chile n=28 |
UK n=1,092 |
Canada n=28 |
Total n=2,581 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex (male, %) | 76.2 | 87.8 | 87.6 | 57.4 | 82.5 | 92.4 | 90 | 97.5 | 78.6 | 62.6 | 53.6 | 74.4 |
|
| ||||||||||||
| Age (years) | 47 (43–55) | 43 (35–50) | 51 (45–58) | 48 (38–55) | 52 (48–60) | 55 (49–61) | 43.5 (37–50) | 45 (39–51) | 54.5 (47–64) | 48.8 (42–56) | 51.5 (38–58) | 48 (41–55) |
|
| ||||||||||||
| Race | ||||||||||||
| White (%) | 77.4 | 0 | 0 | 79.7 | 0 | 89.4 | 67.8 | 0.3 | 0 | 96.1 | 78.6 | 57.7 |
| Black (%) | 0 | 0 | 0 | 12.7 | 0 | 3 | 2.2 | 0 | 0 | 0.5 | 0 | 1.8 |
| Asian (%) | 2.4 | 0 | 100 | 0 | 0 | 7.6 | 0 | 0 | 0 | 2.5 | 3.6 | 12 |
| Latin American (%) | 8.3 | 70.7 | 0 | 5.8 | 0 | 0 | 28.9 | 0 | 85.7 | 0 | 0 | 9 |
| Indian (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 99.7 | 0 | 0 | 0 | 14.1 |
| No registered (%) | 11.9 | 29.3 | 0 | 1.7 | 100 | 0 | 1.1 | 0 | 14.3 | 0.9 | 17.9 | 5.4 |
|
| ||||||||||||
| Deaths at 28 days (%) | 14.3 | 37.8 | 16.1 | 24.1 | 27.5 | 15.2 | 22.2 | 23.2 | 14.3 | 15.9 | 7.1 | 20 |
|
| ||||||||||||
| Lost to follow-up 28d | 2.4 | 3.2 | 10.9 | 5.5 | 15 | 0 | 17.8 | 16.7 | 0 | 0 | 7.1 | 5.4 |
|
| ||||||||||||
| Deaths at 90 days (%) | 20.2 | 56.8 | 22.3 | 36.8 | 27.5 | 25.8 | 33.3 | 35 | 17.9 | 26.2 | 32.1 | 30.9 |
|
| ||||||||||||
| Lost to follow-up 90d | 11.9 | 6.3 | 27 | 11 | 22.5 | 7.6 | 27.8 | 29.8 | 3.6 | 0 | 28.6 | 11.1 |
|
| ||||||||||||
| MELD | 22.7 (18–27) | 30.9 (25–37) | 20.3 (17–26) | 24.7 (21–31) | 25.5 (19–31) | 22.3 (19–26) | 26.5 (21–36) | 22.6 (19–26) | 21.2 (18–27) | 23.4 (21–26) | 21.8 (20–26) | 23.5 (20–28) |
|
| ||||||||||||
| MELD-Na | 21.2 (19–24) | 32.7 (28–38) | 23.5 (20–30) | 28.4 (25–33) | 27.5 (22–33) | 25.3 (23–29) | 30.7 (25–38) | - | 22.6 (19–32) | 26.3 (24–30) | 25.8 (23–30) | 26.8 (23–31) |
|
| ||||||||||||
| mDF | 56.3 (40–87) | 71.6 (50–103) | 38 (21–61) | 52.5 (37–72) | 51.6 (25–77) | 47.3 (35–68) | 53.9 (46–91) | 66.1 (47–97) | 40.9 (22–52) | 55.4 (43 −74) | - | 55.6 (41–79) |
|
| ||||||||||||
| GAHS | 9 (8–10) | 10 (9–11) | 8 (7–9) | 9 (8–10) | 9 (8–11) | - | 9 (8–10) | - | 8 (7–9) | 8 (7–9) | 8 (7–9.7) | 9 (7–10) |
|
| ||||||||||||
| ABIC | 7.6 (7–9) | 8.5 (7–10) | 7.5 (7–9) | 7.9 (7–9) | 8.8 (7–10) | 8.2 (7–9) | 8.3 (7–11) | 7.5 (7–8) | 8.2 (7–9) | 8 (7–9) | 8.1 (7–9) | 7.9 (7–9) |
|
| ||||||||||||
| Alcohol consumption (g/day) | 100 (80–140) | 180 (118–320) | 113 (60–150) | 120 (45–229) | 100 (100–180) | 100 (75–150) | 227.5 (125–584) | - | 130 (92–181) | 131.5 (84–210) | 160 (85–200) | 126 (84–210) |
|
| ||||||||||||
| Corticosteroid treatment (%) | 67.9 | 52.7 | 2.2 | 41.9 | 12.5 | - | 50 | - | 46.4 | 50.1 | 60.7 | 36.3 |
MELD: model for end-stage liver disease, mDF: Maddrey’s discriminant function, GAHS: Glasgow alcoholic hepatitis score, ABIC: age, bilirubin, international normalized ratio and creatinine score